Loading organizations...
SHS Gesellschaft für Beteiligungsmanagement is a specialized German private equity fund dedicated exclusively to the healthcare sector. The firm provides growth capital alongside strategic guidance, leveraging its deep industry network and expertise in critical areas such as market access, reimbursement, marketing, and M&A. Its core approach involves actively supporting portfolio companies through their development phases to help them expand and achieve market leadership within Europe.
The company was founded in 1993 by Bernhard Schirmers and Reinhilde Spatscheck, establishing its base in Tübingen, a prominent healthcare and life sciences hub in southern Germany. Their initial insight recognized the significant potential in innovative healthcare companies, leading them to build a fund focused on nurturing growth in this specialized market. This foundational vision has guided SHS Capital's strategy for over three decades.
SHS Capital targets fast-growing healthcare companies, encompassing both established SMEs and dynamic scale-ups that demonstrate substantial revenue and growth rates. While primarily active in the DACH region, the Nordics, and Benelux, the firm also selectively pursues investment opportunities across the broader European landscape. Its overarching mission is to empower these businesses, transforming them into formidable European healthcare champions and driving progress within the industry.
Key people at SHS Gesellschaft für Beteiligungsmanagement.
Key people at SHS Gesellschaft für Beteiligungsmanagement.
SHS Gesellschaft für Beteiligungsmanagement has 4 tracked investments across 3 companies. The latest tracked deal is $60.0M Series B in Salvia BioElectronics in May 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 26, 2025 | Salvia BioElectronics | $60.0M Series B | Caaj Greebe | BOM, Dolby Family Ventures, EIC Fund, INKEF Capital, Panakes Partners, Thuja Capital |
| Sep 2, 2019 | GNA Biosolutions | $13.5M Series C | TOM Miller | Bayern Kapital, Btov Partners, KFW, MEY Capital Matrix, Occident, Robert Bosch Venture Capital |
| Jul 2, 2015 | GNA Biosolutions | $6.7M Series B | Robert Bosch Venture Capital | Btov Partners, KFW, MEY Capital Matrix, Unternehmertum |
| Jan 8, 2015 | Miracor Medical SA | $5.3M Series B Extension | — | Ralf Kunzmann, Patrick Burgermeister, Delta Partners, Earlybird Venture Capital |